Evonik Evonik

X

Find Troxacitabine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Troxacitabine
Also known as: Troxacitabine, 145918-75-8, Bch-4556, (-)-oddc, 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)pyrimidin-2(1h)-one, 60kqz0388y
Molecular Formula
C8H11N3O4
Molecular Weight
213.19  g/mol
InChI Key
RXRGZNYSEHTMHC-BQBZGAKWSA-N
FDA UNII
60KQZ0388Y

Troxacitabine is a dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts tumor cell proliferation.
1 2D Structure

Troxacitabine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-amino-1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one
2.1.2 InChI
InChI=1S/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1
2.1.3 InChI Key
RXRGZNYSEHTMHC-BQBZGAKWSA-N
2.1.4 Canonical SMILES
C1C(OC(O1)CO)N2C=CC(=NC2=O)N
2.1.5 Isomeric SMILES
C1[C@H](O[C@H](O1)CO)N2C=CC(=NC2=O)N
2.2 Other Identifiers
2.2.1 UNII
60KQZ0388Y
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (2s-cis)-4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-2(1h)-pyrimidinone

2. 1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)cytosine

3. 2r(-)-cis-hmd-cytosine

4. 2r(-)-trans-hmd-cytosine

5. 2s(-)-cis-hmd-cytosine

6. Bch 4556

7. Bch-4556

8. Beta-l-dioxolane-cytidine

9. Hmd-cytosine

10. Troxacitabine

11. Troxacitabine, 2r(-)-cis-isomer

12. Troxacitabine, 2r(-)-trans-isomer

13. Troxacitabine, 2s(-)-trans-isomer

14. Troxacitabine, Cis-(+-)-isomer

15. Troxacitabine, Trans-(+-)-isomer

2.3.2 Depositor-Supplied Synonyms

1. Troxacitabine

2. 145918-75-8

3. Bch-4556

4. (-)-oddc

5. 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)pyrimidin-2(1h)-one

6. 60kqz0388y

7. Cis-dioxolane-c

8. (-)-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)cytosine

9. (2s-cis)-4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-2(1h)-pyrimidinone

10. 4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1h)-one

11. L-oddc

12. (-)-occc

13. Troxacitabine [usan:inn]

14. Unii-60kqz0388y

15. Nsc668281

16. Lamivudine Impurity I

17. (-)-bch 204

18. Lamivudine Impurity I Rs

19. Troxacitabine [mi]

20. (-)-l-.b.-dioxolanec

21. 4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one

22. Troxacitabine [inn]

23. Troxacitabine (usan/inn)

24. Troxacitabine [usan]

25. Schembl18548

26. ((-))-oddc

27. Troxacitabine [who-dd]

28. Chembl359164

29. Chebi:134886

30. Bcpp000031

31. (-)-l-.beta.-dioxolane-cytosine

32. Zinc1642845

33. Akos015967351

34. Db04961

35. Hy-13770

36. Lamivudine Impurity I [ep Impurity]

37. Cs-0007785

38. Lamivudine Impurity I [usp Impurity]

39. D06255

40. 918t758

41. Lamivudine Related Compound (alpha-troxacitabine)

42. J-525143

43. Q7846702

44. (-)-(2s,4s)-1-[2-hydroxymethyl)-1,3-dioxolan-4-yl]cytosine

45. (-)-l-2',3'-dideoxy-3'-oxacytidine; Troxacitabine; Troxatyl

46. 2(1h)-pyrimidinone, 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-

47. 2(1h)-pyrimidinone, 4-amino-1-(-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2s-cis)-

48. 4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-1,2-dihydropyrimidin-2-one

49. Ltt

2.4 Create Date
2005-08-01
3 Chemical and Physical Properties
Molecular Weight 213.19 g/mol
Molecular Formula C8H11N3O4
XLogP3-1.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count2
Exact Mass213.07495584 g/mol
Monoisotopic Mass213.07495584 g/mol
Topological Polar Surface Area97.4 Ų
Heavy Atom Count15
Formal Charge0
Complexity328
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in leukemia (myeloid).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Troxacitabine is a beta-L-nucleoside analog, which has shown preclinical antitumor activity in human xenograft tumor models and antileukemic response in patients with relapsed myeloid leukemia.


5.2 MeSH Pharmacological Classification

Anti-HIV Agents

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)


Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


5.3 Mechanism of Action

Troxacitabine is activated by cellular kinases and incorporated into DNA, inhibiting its replication. In contrast to other cytosine nucleoside analogs, troxacitabine is resistant to inactivation by cytidine deaminase (CD).


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY